MNG464
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.609
- INTERFERON_GAMMA_RESPONSE+0.555
- ANDROGEN_RESPONSE+0.537
- IL6_JAK_STAT3_SIGNALING+0.526
- PROTEIN_SECRETION+0.492
- INTERFERON_ALPHA_RESPONSE+0.475
- ALLOGRAFT_REJECTION+0.446
- INFLAMMATORY_RESPONSE+0.442
- IL2_STAT5_SIGNALING+0.383
- TGF_BETA_SIGNALING+0.376
Top 10 suppressed
- MYC_TARGETS_V2-0.403
- E2F_TARGETS-0.395
- OXIDATIVE_PHOSPHORYLATION-0.307
- PANCREAS_BETA_CELLS-0.282
- G2M_CHECKPOINT-0.232
- KRAS_SIGNALING_DN-0.183
- BILE_ACID_METABOLISM-0.179
- FATTY_ACID_METABOLISM-0.179
- SPERMATOGENESIS-0.146
- NOTCH_SIGNALING-0.135
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53933_S131 | — | cohortA1 | 0.881 |
| 2 | BS_3MYEMXPQ | Med | Medulloblastoma | 0.878 |
| 3 | SRR12202437 | — | — | 0.875 |
| 4 | SRR23303760 | — | — | 0.866 |
| 5 | SJEPD032296_D1.RNA-Seq | EPN | Anaplastic EPN | 0.865 |
| 6 | SJEPD030512_D1.RNA-Seq | EPN | Supratentorial EPN | 0.864 |
| 7 | MNG1175 | — | — | 0.861 |
| 8 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.856 |
| 9 | SRR10900571 | — | — | 0.853 |
| 10 | SAMN03290930 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.609 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.555 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.537 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.526 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.492 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.475 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.446 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.442 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.383 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.376 | Inavolisib | — uncovered |
| HYPOXIA | 0.353 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.335 | Inavolisib | — uncovered |
| COMPLEMENT | 0.321 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.296 | Inavolisib | — uncovered |
| APOPTOSIS | 0.289 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.278 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.226 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.152 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |